This clinical report provides current recommendations regarding the selection and use of drugs in preparation for pediatric emergencies. It is not intended to be a comprehensive list of all medications that may be used in all emergencies. When possible, dosage recommendations are consistent with those used in current emergency references such as the Advanced Pediatric Life Support and Pediatric Advanced Life Support textbooks and the recently revised American Heart Association resuscitation guidelines.
Initial dose: 0.1 mg/kg IV (maximum: 6 mg for first dose) as rapidly as possible, followed by immediate rapid flush of the IV catheter with 5-10 mL of normal saline. A 2-syringe technique is preferred; a larger flush of up to 20 mL may be helpful in older children. The most proximal IV site possible should be used. Adenosine may be given intraosseously if IV access has not been achieved.
Subsequent doses
If no AV block occurs and there is no response within 30 s, give double the initial dose (0.2 mg/kg, up to 12 mg maximum for second/subsequent doses) followed by immediate rapid saline flush as described above.
Note
Continuous electrocardiographic monitoring should be employed during use. A defibrillator must be immediately available. Warning
Contraindicated in patients who have had a heart transplant; contraindicated in second-and third-degree AV block or sick-sinus syndrome unless a pacemaker has been placed. Albuterol Indication Asthma exacerbation, bronchospasm Dosage
Intermittent treatment with 0.5% nebulizer solution (5 mg/mL): minimum dose 2.5 mg (0.5 mL) every 20 min for 3 doses, then 0.15-0.30 mg/kg up to 10 mg every 1-4 h as needed. Dilute in a minimum of 2-3 mL of saline solution for adequate nebulization. Continuous/prolonged nebulization: 0.5 mg/kg per h up to 10-15 mg/h diluted in a larger amount of saline by prolonged nebulization (total amount of fluid is determined by particular type of nebulizer delivery device, usually 25-30 mL for 1 h of nebulization). Metered-dose inhaler: 4-8 puffs (90 g per puff) every 15-20 min for 3 doses. Repeat every 1-4 h as needed. A spacer/holding chamber must be used when administering metered-dose inhaler treatments. Administration can be repeated and dose can be adjusted until desired clinical effect unless patient develops symptomatic tachycardia.
Notes
Oxygen is the preferred gas source for nebulization. Supplemental oxygen may be needed when compressed air-driven nebulizers are used or when the oxygen flow rate dictated by the nebulizer device is inadequate to maintain adequate oxygen saturation. Levalbuterol may also be used; the dose is half of the (racemic) albuterol dose listed above. Alprostadil-see prostaglandin E 1 Amiodarone Indication Pulseless ventricular fibrillation (VT) Dosage IV/IO: 5 mg/kg rapid bolus (maximum: 300 mg); may be repeated up to a total daily dose of 15 mg/kg. Indication VT/supraventricular tachycardia with a pulse. Dosage IV/IO: 5 mg/kg (maximum: 300 mg) over 20-60 min. Adjust administration rate to urgency. May be followed by infusion of 5 g/kg per min, increased to maximum of 10 May cause arrhythmias and hypertension. Infusion rates of Ͼ20 g/kg per min may cause peripheral, renal, and splanchnic vasoconstriction and ischemia. Extravascular administration can result in severe skin injury. Phentolamine (dose: 0.1-0.2 mg/kg up to 10 mg diluted in 10 mL of 0.9% sodium chloride) injected intradermally at extravasation site may be helpful for counteracting dermal vasoconstriction. Epinephrine Dosage/formulation Epinephrine is available in 2 concentrations: 1:1000 (1 mg/mL) and 1:10 000 (0.1 mg/mL). Use caution to ensure selection of the appropriate concentration for the route of administration and patient age/condition. To convert mg/kg dosage to mL/kg: 0.01 mg/kg ϭ 0.1 mL/kg of 1:10 000 solution and 0.1 mg/kg ϭ 0.1 mL/kg of 1:1000 solution. Indication Cardiopulmonary resuscitation Dosage IV/IO Newborn infants: 0.01-0.03 mg/kg of 1:10 000 solution.
Older infants/children: 0.01 mg/kg of 1:10 000 solution (maximum: 1 mg), repeated every 3-5 min. ET Newborn infants: 0.03-0.10 mg/kg of 1:10 000 solution.
Older infants/children: 0.1 mg/kg of 1:1000 solution (maximum: 10 mg). Follow ET administration with saline flush or dilute in isotonic saline (1-5 mL) based on patient size. Note IV high-dose epinephrine (0.1 mg/kg) is no longer recommended for routine use in resuscitation. It may be considered in exceptional circumstances such as ␤-blocker poisoning. Indication Anaphylaxis Dosage IM/SC: 0.01 mg/kg of 1:1000 solution (maximum: 0.3-0.5 mg), repeated every 5-20 min. The IM route is preferred for anaphylaxis. Severe reactions (eg, latex allergy) may require IV epinephrine (see above); a continuous infusion of epinephrine may be necessary.
Indication
Continued shock after volume resuscitation Dosage IV infusion: 0. Doses listed above are recommended to achieve dissociative sedation/anesthesia. Lower doses may be used to provide analgesia without full dissociation. Laryngospasm may occur, most often associated with rapid infusion or concomitant upper respiratory infection. It is usually reversible with oxygen administration, repositioning of the airway, and brief positive-pressure ventilation. Rarely, treatment with a muscle relaxant may be required. Atropine or glycopyrrolate may be used to prevent increased salivation. Warning
Be prepared to provide respiratory support. Monitor oxygen saturation. Avoid use in patients with increased ICP or increased intraocular pressure.
Levalbuterol-see albuterol Lidocaine
Indication Ventricular arrhythmias, wide complex tachycardia Dosage IV/IO: 1 mg/kg (maximum: 100 mg), repeat every 5-10 min to desired effect or until maximum dose of 3 mg/kg is given. IV infusion: 20-50 g/kg per min. ET: 2-3 mg/kg, followed by or diluted in isotonic saline (1-5 mL) based on patient size. Note
Recent data suggest that lidocaine is less effective than amiodarone but may be used if amiodarone is not available. There is an increased incidence of apnea when combined with other sedative agents. Monitor oxygen saturation and be prepared to provide respiratory support. Flumazenil may be administered to reverse life-threatening respiratory depression caused by lorazepam; however, it will also counteract the anticonvulsant effects and may precipitate recurrence of seizures. There is an increased incidence of apnea when combined with other sedative agents, particularly benzodiazepines. Be prepared to administer naloxone/nalmefene. Monitor the patient's vital signs and oxygen saturation. Be prepared to provide respiratory support. Nalmefene Indication Apnea/respiratory depression caused by opioid overdose Dosage IV/IM: 0.25-0.50 g/kg every 2 min. Adult dose: 20 mg/min IV infusion up to total maximum dose of 17 mg/kg (maximum loading dose: 1.0-1.5 g).
Warning
May cause hypotension, negative inotropic effect, prolonged QT interval, torsades de pointes, heart block, and cardiac arrest. If Ն50% QRS widening or hypotension occurs during administration of the drug, the remainder of the dose should be held. Cardiologist consultation is strongly recommended when considering the use of this medication. Should not be used with amiodarone or other drugs that prolong QT interval without expert consultation. vascular access has been obtained, any vascular access (IV or IO) is preferred, because tracheal drug administration results in lower, less predictable drug concentrations than intravascular administration. 5 If the endotracheal (ET) route is used, administer the drug with or diluted in 1 to 5 mL of isotonic saline solution followed by manual ventilations. ET administration of naloxone is no longer recommended for neonates. 6 Most of the medications listed in this clinical report are used for airway management, resuscitation, sedation, analgesia, status epilepticus, or asthma. The Committee on Drugs recognizes that gaps exist in pediatric labeling and dosage information for many of these drugs. Despite these gaps, the package inserts, labels, and available medical literature should be consulted for additional information. The continued lack of clinical testing in pediatric populations before Food and Drug Administration approval of therapeutic agents makes it impossible to have the clinical data to support all pediatric dosing recommendations. Although local practice patterns and individual preferences exist for the use and dosage of many of these medications, the information provided in this document includes recommendations that are based on consensus opinion and literature review. References for individual drug indications and dosing are not provided in this report. Dosages should be individualized, taking into account the patient's age, weight, underlying illness, concurrently administered drugs, and known hypersensitivity. This committee recommends use of the current Advanced Pediatric Life Support 7 and Pediatric Advanced Life Support 8 textbooks, updated American Heart Association guidelines, 5 and additional references for more detailed information on pediatric resuscitation algorithms, rapid-sequence intubation (RSI), procedural sedation, and treatment of asthma. 9, 10 For newborn infants, practitioners can consult the Textbook of Neonatal Resuscitation 11 and updated American Heart Association guidelines 6 for detailed information concerning management of neonatal emergencies and appropriate drugs, dosages, and routes of administration. In addition, pre- printed medication cards and/or length-based resuscitation tapes (eg, Broselow tape) should be readily available at all sites that provide medical care for children.
